Status:
UNKNOWN
Prospective Translational Study Investigating Predictors of Outcome in Metastatic Renal Cell Carcinoma Patients Treated With Nivolumab (I-Rene Trial)
Lead Sponsor:
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Collaborating Sponsors:
Ministero della Salute, Italy
Conditions:
Metastatic Renal Cell Carcinoma
Eligibility:
All Genders
18-90 years
Brief Summary
Prospective translational study investigating predictors of outcome in metastatic renal cell carcinoma patients treated with Nivolumab (I-Rene trial)
Detailed Description
Prospective translational study investigating predictors of outcome in metastatic renal cell carcinoma patients treated with Nivolumab (I-Rene trial)
Eligibility Criteria
Inclusion
- Written informed consent
- metastatic renal cell carcinoma (a clear-cell/ not clear-cell)
- Progression to previous treatment with tyrosine kinase inhibitors
- Patients candidates for II-line therapy with Nivolumab (or tyrosine kinase inhibitors-in the control arm)
Exclusion
- none
Key Trial Info
Start Date :
November 29 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 29 2021
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT04891055
Start Date
November 29 2018
End Date
November 29 2021
Last Update
May 18 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fondazione IRCCS Istituto Nazionale Tumori
Milan, Italy, 20133